PALI – palisade bio, inc. (US:NASDAQ)
Stock Stats
News
Palisade Bio (PALI) is now covered by HC Wainwright. They set a "buy" rating and a $7.00 price target on the stock.
Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating [Seeking Alpha]
Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients [Yahoo! Finance]
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
Palisade Bio (PALI) is now covered by Stifel Nicolaus. They set a "buy" rating and a $5.00 price target on the stock.
Form 10-K PALISADE BIO, INC. For: Dec 31
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: Point72 Asset Management, L.P.
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: PERCEPTIVE ADVISORS LLC
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: Squadron Capital Management LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.